Repeated low-dose influenza virus infection causes severe disease in mice: A model for vaccine evaluation

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7841-7851

  Song, Yufeng ^a   Wang, Xiang ^a,d   Zhang, Hongbo ^a   Tang, Xinying ^a   Li, Min ^b   Yao, Jufang ^b   Jin, Xia ^a   Ertl, Hildegund C J ^c   Zhou, Dongming ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c WISTAR INSTITUTE   (United States)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; INFLAMMATION; INFLUENZA A (H1N1); INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA VACCINATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; ANIMAL; C57BL MOUSE; CHICK EMBRYO; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; LUNG; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALIA; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED C57BL;

EID: 84937688991     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00976-15     Document Type: Article

References (48)

1. Tumpey TM, Belser JA. 2009. Resurrected pandemic influenza viruses. Annu Rev Microbiol 63:79-98. http://dx.doi.org/10.1146/annurev.micro.091208.073359.
2. Taubenberger JK, Morens DM. 2008. The pathology of influenza virus infections. Annu Rev Pathol 3:499-522. http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.154316.
3. Thangavel RR, Bouvier NM. 2014. Animal models for influenza virus pathogenesis, transmission, and immunology. J Immunol Methods 410: 60-79. http://dx.doi.org/10.1016/j.jim.2014.03.023.
4. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563. http://dx.doi.org/10.3390/v20801530.
5. Moscona A. 2008. Medical management of influenza infection. Annu Rev Med 59:397-413. http://dx.doi.org/10.1146/annurev.med.59.061506.213121.
6. Pica N, Palese P. 2013. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189-202. http://dx.doi.org/10.1146/annurev-med-120611-145115.
7. Poland GA. 2006. Vaccines against avian influenza-a race against time. N Engl J Med 354:1411-1413. http://dx.doi.org/10.1056/NEJMe068047.
8. Wang G, Zhou F, Buchy P, Zuo T, Hu H, Liu J, Song Y, Ding H, Tsai C, Chen Z, Zhang L, Deubel V, Zhou P. 2014. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin. J Infect Dis 209:676-685. http://dx.doi.org/10.1093/infdis/jit414.
9. Villari P, Manzoli L, Boccia A. 2004. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 22:3475-3486. http://dx.doi.org/10.1016/j.vaccine.2004.01.068.
10. Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, Bian A, Li Y, Li H, Erikson J, Xiang Z, Ertl HC. 2010. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18:2182-2189. http://dx.doi.org/10.1038/mt.2010.202.
11. Bodewes R, Rimmelzwaan GF, Osterhaus AD. 2010. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 9:59-72. http://dx.doi.org/10.1586/erv.09.148.
12. Kim JI, Park S, Lee S, Lee I, Heo J, Hwang MW, Bae JY, Kim D, Jang SI, Park MS. 2013. DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation. J Microbiol 51:866-871. http://dx.doi.org/10.1007/s12275-013-3428-7.
13. Zhou F, Wang G, Buchy P, Cai Z, Chen H, Chen Z, Cheng G, Wan XF, Deubel V, Zhou P. 2012. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenzaH5N1 viruses. J Virol 86:6970-6978. http://dx.doi.org/10.1128/JVI.06930-11.
14. Regoes RR, Longini IM, Feinberg MB, Staprans SI. 2005. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med 2:e249. http://dx.doi.org/10.1371/journal.pmed.0020249.
15. Regoes RR. 2012. The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies. PLoS Comput Biol 8:e1002767. http://dx.doi.org/10.1371/journal.pcbi.1002767.
16. Banyard AC, Healy DM, Brookes SM, Voller K, Hicks DJ, Nunez A, Fooks AR. 2014. Lyssavirus infection: 'low dose, multiple exposure' in the mouse model. Virus Res 181:35-42. http://dx.doi.org/10.1016/j.virusres.2013.12.029.
17. Gujar SA, Mulrooney-Cousins PM, Michalak TI. 2013. Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis. J Virol 87:1035-1048. http://dx.doi.org/10.1128/JVI.01363-12.
18. Zhang R, Rong X, Pan W, Peng T. 2011. Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1. Scand J Infect Dis 43:216-220. http://dx.doi.org/10.3109/00365548.2010.539258.
19. Lamoreaux L, Roederer M, Koup R. 2006. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 1:1507-1516. http://dx.doi.org/10.1038/nprot.2006.268.
20. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, Angelosanto JM, Laidlaw BJ, Yang CY, Sathaliyawala T, Kubota M, Turner D, Diamond JM, Goldrath AW, Farber DL, Collman RG, Wherry EJ, Artis D. 2011. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12:1045-1054. http://dx.doi.org/10.1038/ni.2131.
21. Wu S, Metcalf JP, Wu W. 2011. Innate immune response to influenza virus. Curr Opin Infect Dis 24:235-240. http://dx.doi.org/10.1097/QCO.0b013e328344c0e3.
22. Sakamoto M, Ida S, Takishima T. 1984. Effect of influenza virus infection on allergic sensitization to aerosolized ovalbumin in mice. J Immunol 132:2614-2617.
23. Pulendran B, Maddur MS. 2015. Innate immune sensing and response to influenza. Curr Top Microbiol Immunol 386:23-71. http://dx.doi.org/10.1007/82_2014_405.
24. Ichinohe T, Pang IK, Iwasaki A. 2010. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 11:404-410. http://dx.doi.org/10.1038/ni.1861.
25. Ichinohe T. 2010. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Rev Vaccines 9:1315-1324. http://dx.doi.org/10.1586/erv.10.118.
26. Iwasaki A, Pillai PS. 2014. Innate immunity to influenza virus infection. Nat Rev Immunol 14:315-328. http://dx.doi.org/10.1038/nri3665.
27. Stout-Delgado HW, Vaughan SE, Shirali AC, Jaramillo RJ, Harrod KS. 2012. Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin. J Immunol 188:2815-2824. http://dx.doi.org/10.4049/jimmunol.1103051.
28. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles RJ, Ting JP. 2009. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30:556-565. http://dx.doi.org/10.1016/j.immuni.2009.02.005.
29. Thomas PG, Dash P, Aldridge JR, Jr, Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, Doherty PC, Kanneganti TD. 2009. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30:566-575. http://dx.doi.org/10.1016/j.immuni.2009.02.006.
30. Schroder K, Tschopp J. 2010. The inflammasomes. Cell 140:821-832. http://dx.doi.org/10.1016/j.cell.2010.01.040.
31. McAuley JL, Tate MD, MacKenzie-Kludas CJ, Pinar A, Zeng W, Stutz A, Latz E, Brown LE, Mansell A. 2013. Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe patho-physiology and disease. PLoS Pathog 9:e1003392. http://dx.doi.org/10.1371/journal.ppat.1003392.
32. Kao W, Costanzo MR. 2000. Sudden death in heart failure patients: effects of optimized medical therapy. J Heart Lung Transplant 19:S32-S37. http://dx.doi.org/10.1016/S1053-2498(99)00108-4.
33. Ronni T, Sareneva T, Pirhonen J, Julkunen I. 1995. Activation of IFNalpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol 154:2764-2774.
34. Ronni T, Matikainen S, Sareneva T, Melen K, Pirhonen J, Keskinen P, Julkunen I. 1997. Regulation of IFN-alpha/beta, MxA, 2',5'-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells. J Immunol 158:2363-2374.
35. Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, Bunn J, Suratt BT, Haynes L, Rincon M. 2012. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5:258-266. http://dx.doi.org/10.1038/mi.2012.2.
36. Quinones-Parra S, Loh L, Brown LE, Kedzierska K, Valkenburg SA. 2014. Universal immunity to influenza must outwit immune evasion. Front Microbiol 5:285. http://dx.doi.org/10.3389/fmicb.2014.00285.
37. Quan FS, Compans RW, Nguyen HH, Kang SM. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82:1350-1359. http://dx.doi.org/10.1128/JVI.01615-07.
38. Soboll G, Horohov DW, Aldridge BM, Olsen CW, McGregor MW, Drape RJ, Macklin MD, Swain WF, Lunn DP. 2003. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 94:47-62. http://dx.doi.org/10.1016/S0165-2427(03)00060-6.
39. Manuela Q, Gianbattista L, Gianpiero L, Antonella DD. 2011. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers in South Apulia, Italy: a pilot study. J Clin Med Res 3:291-295. http://dx.doi.org/10.4021/jocmr647w.
40. Couch RB, Bayas JM, Caso C, Mbawuike IN, Lopez CN, Claeys C, El Idrissi M, Herve C, Laupeze B, Oostvogels L, Moris P. 2014. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 14:425. http://dx.doi.org/10.1186/1471-2334-14-425.
41. Carmona Martinez A, Salamanca de la Cueva I, Boutet P, Vanden Abeele C, Smolenov I, Devaster JM. 2014. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Hum Vaccin Immunother 10:1959-1968. http://dx.doi.org/10.4161/hv.28743.
42. Otten RA, Adams DR, Kim CN, Jackson E, Pullium JK, Lee K, Grohskopf LA, Monsour M, Butera S, Folks TM. 2005. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 191:164-173. http://dx.doi.org/10.1086/426452.
43. Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G. 2013. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 87:3538-3548. http://dx.doi.org/10.1128/JVI.02863-12.
44. Kersh EN, Luo W, Adams DR, Srinivasan P, Smith JM, Promadej-Lanier N, Ellenberger D, Garcia-Lerma JG, Butera S, Otten R. 2009. Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model. AIDS Res Hum Retroviruses 25:905-917. http://dx.doi.org/10.1089/aid.2008.0287.
45. Belser JA, Szretter KJ, Katz JM, Tumpey TM. 2009. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 73:55-97. http://dx.doi.org/10.1016/S0065-3527(09)73002-7.
46. Belser JA, Katz JM, Tumpey TM. 2011. The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4:575-579. http://dx.doi.org/10.1242/dmm.007823.
47. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, Sun X, Carney PJ, Villanueva JM, Stevens J, Katz JM, Tumpey TM. 2013. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501:556-559. http://dx.doi.org/10.1038/nature12391.
48. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497.